

AstraZeneca



TPW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jean-Claude Arnould	371 Filing Date: 09/29/2004
Application No.: 10/509,633	Attorney Docket No.: 100467-1P US
PCT Application No.: PCT/GB03/01405	Examiner: Not yet assigned
Title: Chemical Compounds	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 24th June 2005

Lucy Padget

Signature
Lucy Padget

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the first Office Action on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100467-1P US.

Respectfully submitted,



Name: Lucy Padget
Dated: 24th June 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760

Enclosures: Form SB08A
Form SB08B
Documents



PTO/SB/08A (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	US1	US-4,533,672 A	08-06-1985	Imperial Chemical Industries PLC	
	US2	US-3,901,914	08-26-1975	Merck & Co., Inc.	
	US3	US-4,952,584	08-28-1990	Beecham Group p.l.c.	
	US4	US-3,166,570	01-19-1965	American Home Products Corporation	
	US5	US-3,168,526	02-02-1965	The Upjohn Company	
	US6	US-3,037,031	05-29-1962	Warner-Lambert Pharmaceutical Company	
	US7	US-2,984,670	05-16-1961	The Upjohn Company	
	US8	US-2,890,223	06-09-1959	Research Company	
	US9	US-2,849,454	08-26-1958	The Upjohn Company	
	US10	US-2,802,003	08-06-1957	The Geschickter Fund for Medical Research, Inc.	
	US11	US-2,991,291	07-04-1961	The Upjohn Company	
	US12	US-2,883,394	04-21-1959	Geigy Chemical Corporation	
	US13	US-2,789,984	04-23-1957	The Upjohn Company	
	US14	US-5,424,329	06-13-1995	Warner-Lambert Company	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AA	WO 01/92224 A1	12-06-2001	AstraZeneca AB		<input type="checkbox"/>
	AB	WO 02/70478 A1	09-12-2002	AstraZeneca AB		<input type="checkbox"/>
	AC	EP 1297833 A1	04-02-2003	Pfizer Products Inc.		<input type="checkbox"/>
	AD	CH 414639 +English Abstract	12-30-1966	Sandoz Ltd.		<input type="checkbox"/>
	AE	WO 98/39323 A1	09-11-1998	Baylor University		<input type="checkbox"/>
	AF	WO 99/29660 A1	06-17-1999	Astra Pharmaceuticals Ltd.		<input type="checkbox"/>
	AG	WO 99/29661 A1	06-17-1999	Astra Pharmaceuticals Ltd.		<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 2 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AH	WO 99/51598 A1	10-14-1999	Neurogen Corporation		<input type="checkbox"/>
	AI	WO 99/51600 A1	10-14-1999	Neurogen Corporation		<input type="checkbox"/>
	AJ	WO 00/48606 A1	08-24-2000	Oxigene, Inc.		<input type="checkbox"/>
	AK	WO 00/66585 A1	11-09-2000	Neurogen Corporation		<input type="checkbox"/>
	AL	WO 01/19794 A2	03-22-2001	Baylor UniversityS		<input type="checkbox"/>
	AM	WO 01/29025 A2	04-26-2001	Merck & Co., Inc.		<input type="checkbox"/>
	AN	WO 01/82909 A2	11-08-2001	Asta Medica AG		<input type="checkbox"/>
	AO	EP 0372962 B1	07-20-1994	Beecham Pharmaceuticals		<input type="checkbox"/>
	AP	EP 0393575 B1	03-16-1994	G.D. Searle & Co.		<input type="checkbox"/>
	AQ	JP 200080295 A2 +English Abstract	03-21-2000	Konica Co., Japan		<input type="checkbox"/>
	AR	EP 0107963 B1	04-01-1987	Imperial Chemical Industries PLC		<input type="checkbox"/>
	AS	ES 227606 +English Abstract	03-01-1957	Drogas Vacunas y Sueros S.A.		<input type="checkbox"/>
	AT	GB 942548	11-27-1963	Sandoz Ltd.		<input type="checkbox"/>
	AU	GB 873777	07-26-1961	The Upjohn Company		<input type="checkbox"/>
	AV	GB 869775	06-07-1961	The Upjohn Company		<input type="checkbox"/>
	AW	GB 834028	05-04-1960	The Upjohn Company		<input type="checkbox"/>
	AX	GB 839628	06-29-1960	May & Baker Ltd.		<input type="checkbox"/>
	AY	GB 770370	03-20-1957	Romeo Justoni & Raffaele Pessina		<input type="checkbox"/>
	AZ	CH 380129 +English Abstract	09-15-1964	Sandoz Ltd.		<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 3 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	FR 1388973 +English Abstract	02-12-1965	N. V. Philips' Gloeilampenfabriek en		<input type="checkbox"/>
	BB	GB 1033253	06-22-1966	American Cyanamid Company		<input type="checkbox"/>
	BC	GB 886684	01-10-1962	The Upjohn Company		<input type="checkbox"/>
	BD	GB 841524	07-20-1960	May & Baker Ltd.		<input type="checkbox"/>
	BE	FR 1238756 +English Abstract	02-12-1960	Laboratoires Francais de Chimiotherapie		<input type="checkbox"/>
	BF	GB 832855	04-13-1960	Imperial Chemical Industries Ltd.		<input type="checkbox"/>
	BG	GB 807620	01-21-1959	Imperial Chemical Industries Ltd.		<input type="checkbox"/>
	BH	WO 94/14770 A1	07-07-1994	SmithKline Beecham PLC		<input type="checkbox"/>
	BI	WO 99/12905 A1	03-18-1999	L'Oreal		<input type="checkbox"/>
	BJ	EP 0708091 A1	04-24-1996	Sumitomo Pharmaceuticals Co., Ltd.		<input type="checkbox"/>
	BK	SU 175967 +English Abstract	10-26-1965	Yakubovich, A. Ya.; Gitel, P. O.; Belyaeva, I. N.; Smolyanitskaya, V. V.		<input type="checkbox"/>
	BL	CH 402860 +English Abstract	05-31-1966	Sandoz Ltd.		<input type="checkbox"/>
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467

SHEET 1 of 5

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	SHEPPARD, G. S. '3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists' <i>Journal Of Medicinal Chemistry</i> vol. 37, no. 13, 2011-2032, 1994	<input type="checkbox"/>
	AB	KWONG, F. Y & BUCHWALD, S. L. 'A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols' <i>Org. Lett.</i> Vol. 4, no. 20, 3517-3520, 2002.	<input type="checkbox"/>
	AC	DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissensschaften' Database Accession No. 8172403	<input type="checkbox"/>
	AD	DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissensschaften' Database Accession No. 183150, reaction 2 of 4	<input type="checkbox"/>
	AE	DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissensschaften' Database Accession No. 5433848	<input type="checkbox"/>
	AF	MONGE A ET AL 'New indole and pyridazinoindole analogs - synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation' <i>Archiv Der Pharmazie</i> vol. 328, no. 10, pp. 689-698, 1995.	<input type="checkbox"/>
	AG	ALEKSANDRZAK, K. McGOWN, A. T & HADFIELD, J. A. 'Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4' <i>Anti-Cancer Drugs</i> vol. 9, pp.545-550, 1998.	<input type="checkbox"/>
	AH	McGOWN, A. T. & FOX, B. W. 'Structural and biochemical comparison of the anti-mitotic agents colchicines, combretastatin A4 and amphethinile' <i>Anti-Cancer Drug Design</i> vol. 3, pp. 249-254, 1989.	<input type="checkbox"/>
	AI	GALBRAITH, S. M ET AL. 'Effects of combrestatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo' <i>Anti-Cancer Research</i> vol. 21, pp. 93-102, 2001.	<input type="checkbox"/>
	AJ	BOLTON, D ET AL 'Synthesis and potential anxiolytic activity of 4-amino-pyrido[2,3-b]indoles' <i>Bioorganic & Medicinal Chemistry Letters</i> vol. 3, no. 10, pp. 1941-1946, 1993.	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 2 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AK	BLACKBURN, T, P. '11-amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, a novel GABA _A modulator with Potential anxiolytic activity' <i>Bioorganic & Medicinal Chemistry Letters</i> vol. 4, no. 2, pp. 279-284, 1994.	<input type="checkbox"/>
	AL	McGOWN, A, T ET AL 'Pre-clinical studies of a novel anti-mitotic agent, amphetamine' <i>Br J Cancer</i> vol. 57, pp. 157-159, 1988.	<input type="checkbox"/>
	AM	McGOWN, A, T. & FOX, B, W. 'Interaction of the novel agent amphetamine with tubulin' <i>Br J Cancer</i> vol. 59, pp. 865-868, 1989.	<input type="checkbox"/>
	AN	NEWELL, D, R ET AL 'Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics' <i>British Journal of Cancer</i> vol. 81(5), pp. 760-768, 1999.	<input type="checkbox"/>
	AO	DARK, G, G. 'Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature' <i>Cancer Research</i> vol. 57, pp. 1829-1834, 1997.	<input type="checkbox"/>
	AP	PLAYER, M, R & SOWELL, J, W. 'Synthesis of 1,3-disubstituted-2-amino-5-hydroxyindoles by reductive aromatization' <i>J Heterocyclic Chem</i> vol. 30 (125), pp. 125 - 128, 1993.	<input type="checkbox"/>
	AQ	HESS, S ET AL. '7-deazaadenines bearing polar substituents: structure-activity relationships of new A ₁ and A ₃ adenosine receptor antagonists' <i>J Med Chem</i> vol. 43, pp. 4636-4646, 2000.	<input type="checkbox"/>
	AR	FUSE, E ET AL 'Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity' <i>Journal of the National Cancer Institute</i> vol. 86, no. 13, 1994.	<input type="checkbox"/>
	AS	EGER, K ET AL 'Synthesis of substituted indoles and pyrimido[4,5-b]indoles by dehydration of tetrahydroindoles and tetrahydropyrimidoindoles' <i>Liebigs Ann Chem</i> pp. 465-470, 1993.	<input type="checkbox"/>
	AT	KEGLEVIC, D & GOLES, D 'Indole compounds. VI. Syntheses of indole thioethers by direct cyclization of phenylhydrazine hydrochlorides and aliphatic acetals under mild conditions' <i>Croatica Chemica Acta</i> vol. 42, pp. 513-521, 1970.	<input type="checkbox"/>
	AU	DESATY, D ET AL 'The synthesis of N-acetylserotonin' <i>Biochem Biophys Acta</i> vol. 62, pp. 179-180, 1962.	<input type="checkbox"/>
	AV	MASHIMA, H & MATSUMURA, M. 'Roles of external ions in the excitation-contraction coupling of frog skeletal muscle' <i>Japan J Physiol</i> vol. 12, pp 639-653, 1962.	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 3 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AW	HEATH-BROWN, B & PHILPOTT, P. G. 'Studies in the indole series. Part 1. Indolylalkylamines' <i>J Chem Soc</i> pp. 7165-7078, 1965.	<input type="checkbox"/>
	AX	DESAI, H. K. & USGAONKAR, R. N. 'Isocoumarins. Part 1. Synthesis of 4-Methylisocoumarins' <i>Jour Indian Chem Soc</i> vol. 41, no. 12, pp. 821 – 829, 1964.	<input type="checkbox"/>
	AY	HEACOCK, R. A. & HUTZINGER, O. 'The preparation of the hydroxyskatoles and 5,6-dihydroxyskatole' <i>Canadian Journal of Chemistry</i> vol. 42, pp. 514 – 521, 1964.	<input type="checkbox"/>
	AZ	MA, J, C, N & WARNHOFF, E, W. 'On the use of nuclear magnetic resonance for the detection, estimation and characterization of N-methyl groups' <i>Canadian Journal of Chemistry</i> vol. 43, pp. 1849 – 1869, 1965.	<input type="checkbox"/>
	BA	BENIGNI, J, D & MINNIS, R, L. 'The synthesis of 5,6-dihydroxyindole and some of its derivatives (1)' <i>J Heterocyclic Chem</i> vol. 2, pp. 387 – 392, 1965.	<input type="checkbox"/>
	BB	MARCHAND, B ET AL 'Preparative chemistry of indole compounds. 1. Preparation of phenylhydrazones of pyruvic acid esters from methyloxalacetic esters and diazonium salts and conversion of these compounds into indole-2-carboxylic esters' <i>J Prakt Chem</i> vol. 13, pp. 54-57, 1961. +English Abstract	<input type="checkbox"/>
	BC	TABORSKY, R, G. & DELVIGS, P. 'Synthesis of some substituted tryptophols of possible physiological importance and a study with 3-(2-acetoxyethyl)-5-methoxyindole (5-methoxytryptophol O-acetate) on sexual maturation' <i>J Med Chem</i> vol. 9, pp. 251 – 254, 1966.	<input type="checkbox"/>
	BD	TABORSKY, R, G ET AL '6-hydroxyindoles and the metabolism of melatonin' <i>J Med Chem</i> vol. 8(6), pp 855-858, 1965.	<input type="checkbox"/>
	BE	TABORSKY, R, G ET EL 'Synthesis and preliminary pharmacology of some 1-methylindoles' <i>J Med Chem</i> vol. 8(4), pp. 460 – 466, 1965.	<input type="checkbox"/>
	BF	ARUTYUNYAN, G, S. ET AL 'Relations between chemical structure and pharmacological activity of 5-alkoxytryptamines' <i>Farmakol Toksikol</i> vol. 27(6), pp. 681 – 686, 1964. +English Abstract	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 4 of 5

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BG	KRASNYKH, P, G ET AL 'Radioprotective action of 5-methoxytryptamine and other alkoxytryptamines' <i>Radiobiologiya</i> vol. 2(1), pp. 156-160, 1962. +English Abstract	<input type="checkbox"/>
	BH	SHAGALOV, N, P. ET AL 'Indole derivatives. XXI. Synthesis of 4- and 6-chloroindolybutyric acids' <i>Zh Obshch Khim</i> vol. 34(5), pp. 1592 – 1595, 1964. +English Abstract	<input type="checkbox"/>
	BI	KEGLEVIC, D ET AL 'The synthesis of 3,5-disubstituted indoles by cyclization under mild conditions' <i>Croat Chem Acta</i> vol. 33, pp. 83-88, 1961. +English Abstract	<input type="checkbox"/>
	BJ	GREENBERG, A, J. & KETCHAM, R 'Determination of urinary indolic metabolites' <i>Journal of Pharmaceutical Sciences</i> vol. 67(4), pp. 478 – 480, 1978.	<input type="checkbox"/>
	BK	COTTERILL ET AL 'Cyclopropamitosenes, Novel Bioreductive Anticancer Agents. Synthesis, Electrochemistry, and Biological Activity of 7-Substituted Cyclopropamitosenes and Related Indolequinones' <i>J Med Chem</i> vol.37(22), pp. 3834 – 3843, 1994	<input type="checkbox"/>
	BL	COTTERILL ET AL 'Cyclopropamitosenes, Novel Bioreductive Anticancer Agents. Synthesis, 7-Methoxycyclopropamitosene and Related Indolequinones', <i>Tetrahedron</i> vol. 50(25), pp. 7657 – 7674, 1994.	<input type="checkbox"/>
	BM	MOODY ET AL 'Synthesis and Biological Activity of Thiazolylindolequinones, Analogues of the Natural Product BE 10988', <i>J Med Chem</i> vol. 38(6), pp. 1039 – 1043, 1995.	<input type="checkbox"/>
	BN	MOODY ET AL 'Synthesis and Cytotoxic of Thiazolyl Indolequinones', <i>Anti-Cancer Drugs</i> vol. 10, pp. 577 – 589, 1999.	<input type="checkbox"/>
	BO	CHIKVAIDZE ET AL 'Soobshch Akad Nauk Gruz' Bulletin of the Academy of Sciences of Georgia, vol. 141(3), pp. 545-548, 1991. +English Abstract	<input type="checkbox"/>
	BP	BESWICK ET AL 'The Synthesis of 4 – Substituted Indoles via Arenetricarbonylchromium(0) Complexes' <i>Tetrahedron</i> vol. 44(23), pp. 7325 – 7334, 1988.	<input type="checkbox"/>
	BQ	NECHVATAL & WIDDOWSON 'A New Synthesis of 4-Substituted Indoles via Tricarbonylarenechromium(0) Complexes' <i>J Chem Soc Chem Commun</i> vol. 8, pp. 467-468, 1982.	<input type="checkbox"/>
	BR	DICKENS ET AL 'Transition Metal Medicated Thiation of Aromatic Rings' <i>Tetrahedron</i> vol. 47(40), pp. 8621 – 8634, 1991.	<input type="checkbox"/>
	BS	FUKUDA ET AL 'Directed C-7 Lithiation of 1-(2,2-Diethylbutanoyl)indoles' <i>Tetrahedron</i> vol. 55(30), pp. 9151 – 9162, 1999.	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BT	ALEXANDRZAK ET AL 'Antimitotic Activity of Diaryl Compounds with Structural Features Resembling Combretastatin A-4' <i>Anticancer Drugs</i> vol. 9(6), pp. 545-550, 1998.	<input type="checkbox"/>
	BU	MCGOWAN & FOX 'Structural and Biochemical Comparison of the Anti-Mitotic Agents Colchicine, Combretastatin A4 and Amphelthinile' <i>Anticancer Drug Des</i> vol. 3(4), pp. 249-254, 1989.	<input type="checkbox"/>
	BV	MCGOWAN & FOX 'Interaction of the Novel Agent Amphethinile with Tubulin', <i>British Journal of Cancer</i> vol. 59(6), pp. 865 - 868, 1989.	<input type="checkbox"/>
	BW	MCGOWAN & FOX 'Pre-Clinical Studies of a Novel Anti-Mitotic Agent, Amphethinile' <i>British Journal of Cancer</i> vol. 57(2), pp. 157 - 159, 1988.	<input type="checkbox"/>
	BX	GAIRNS ET AL 'Synthesis of Fused 1 λ^4 , 2-Thiazines(2-Azathiabenzene)s' <i>J Chem Soc Perkin Trans</i> vol. 1(3), pp. 483 - 489, 1986.	<input type="checkbox"/>
	BY	ALLEN 'Synthesis of Indole-2-Carboxylic Acid Esters', <i>Synth Commun</i> vol. 29(3), pp. 447 - 455, 1999.	<input type="checkbox"/>
	BZ	DUNAN & ANDRAKO 'Synthesis of 2-(N,N-Dialkylaminomethyl)-7-Phenylthioindoles', <i>J Pharm Sci</i> vol. 57(6), pp. 979 - 983, 1968.	<input type="checkbox"/>
	CA	SOMEI & NATSUME 'Photochemical Rearrangements for the Synthesis of 3-,4- and 6-Substituted Indoles', <i>Tetrahedron Lett</i> vol. 27, pp. 2451 - 2454, 1973.	<input type="checkbox"/>
	CB	MIRZIASHVILI ET AL <i>Khim Geterotsikl Soedin</i> vol. 1, pp. 54 - 56, 1991. +English Abstract	<input type="checkbox"/>
	CD	NERENBERG ET AL 'Radioimmunoassay of Oxfendazole in Bovine, Equine, or Canine Plasma or Serum', <i>J Pharm Sci</i> vol. 67(11), pp. 1553 - 1557, 1978.	<input type="checkbox"/>
	CE	CHIKVAIDZE ET AL 'New Indole Derivatives: Synthesis and Antibacterial Activity' <i>Pharmaceutical Chemistry Journal</i> , Vol. 32, No. 1, pp.30-33, 1998	<input type="checkbox"/>
	CF	MCCORMICK ET AL 'Characterization and Synthesis of a New Calcium Antagonist from the Venom of a Fishing Spider', <i>Tetrahedron Lett</i> vol. 49, No. 48, pp. 11155-11168, 1993	<input type="checkbox"/>
	CG	CHIKVAIDZE ET AL 'Indole Derivatives 138.* Synthesis of Some New Sulfur-Containing Derivatives of Indole', <i>Chem Heterocycl Compd</i> , Vol. 27 No. 11 pp. 1218-1221, 1991	<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.